NFKB1 and metabolic dysfunction-associated steatohepatitis: In conclusion, the experimental results show that the molecular mechanism of GSG in the treatment of NASH is mainly reflected in the inhibition of the NF-κB signaling pathway and its downstream inflammatory and apoptosis signals.